Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2054-2060

  Wu, Chun Ying ^a,c,d   Wu, Ming Shiang ^a   Chiang, En Pei ^e   Chen, Yi Ju ^c   Chen, Chien Jen ^b   Chi, Nai Hui ^a   Shin, Ying Ting ^e   Chen, Gran Hum ^a   Lin, Jaw Town ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLASMA; PROGNOSIS; ROC CURVE; SERUM; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247533634     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2299     Document Type: Article

References (45)

1. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
2. la-aho R, Kahari VM. Collagenases in cancer. Biochimie 2005;87:273-86.
3. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10: 415-33.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
5. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
6. Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999;878:212-27.
7. Zucker S, Lysik RM, Gurfinkel M, et al. Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma. J Immunol Methods 1992;148:189-98.
8. Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:5365-9.
9. Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993;53:140-6.
10. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 2005;236:125-32.
11. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005;116:422-7.
12. Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 2000;20:1307-10.
13. Hayasaka A, Suzuki N, Fujimoto N, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996;24:1058-62.
14. Endo K, Maehara Y, Baba H, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997;17:2253-8.
15. Torii A, Kodera Y, Uesaka K, et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 1997;84:133-6.
16. Decock J, Hendrickx W, Wildiers H, et al. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin Exp Metastasis 2005;22:495-502.
17. Kirman I, Jain S, Cekic V, et al. Altered plasma matrix metalloproteinase-9/tissue metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer. Surg Endosc 2006; 20:706-9.
18. Jung K. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? J Neuroimmunol 2005;162:1-2.
19. Mannello F, Luchetti F, Canonico B, Papa S. Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003;49: 1956-7.
20. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003;49:339-40.
21. Jung K, Laube C, Lein M, et al. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 1998;44:1060-2.
22. Makowski GS, Ramsby ML. Interaction of amorphous calcium phosphate with fibrin in vitro causes decreased fibrinolysis and altered protease profiles: implications for atherosclerotic disease. Inflammation 2001;25:319-29.
23. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001;314: 241-4.
24. Dragutinovic VV, Radovanovic NS, Izrael-Zivkovic LT, Vrvic MM. Detection of gelatinase B activity in serum of gastric cancer patients. World J Gastroenterol 2006;12:105-9.
25. Rauvala M, Puistola U, Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 2005;99:656-63.
26. Chen W, Abnet CC, Wei WQ, et al. Serum markers as predictors of esophageal squamous dysplasia and early cancer. Anticancer Res 2004;24: 3245-9.
27. Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001;19: 4245-51.
28. Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003;104:617-23.
29. Sier CF, Kubben FJ, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-7.
30. Hanemaaijer R, Verheijen JH, Maguire TM, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2000;86:204-7.
31. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990;127:103-8.
32. Fujisawa T, Kato Y, Terada A, Iguchi K, Kamiya H. Matrix metalloproteinase-9 in peripheral blood eosinophils. Int Arch Allergy Immunol 1999;120 Suppl 1: 65-9.
33. Kubben FJ, Sier CF, van DW, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006;94:1035-40.
34. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000; 20:1085-91.
35. Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001; 95:1-4.
36. Yang SF, Hsieh YS, Lin CL, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354:91-9.
37. Tamura M, Oda M, Matsumoto I, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 2004;11:928-33.
38. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005;11:5158-66.
39. Laack E, Scheffler A, Burkholder I, et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer NSCLC). Lung Cancer 2005;50:51-8.
40. Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005;183:29-42.
41. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP. Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 2004;30:560-4.
42. Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003;39: 1948-56.
43. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000; 20:1311-6.
44. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003; 95:634-5.
45. Kattan MW, Karpeh MS, Mazymdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647-50.